Sensus Healthcare, Inc. (SRTS) company profile
Close on Nov 13, 2026Market cap $38.27MP/E –Yield –
About Sensus Healthcare
Surgical & Medical Instruments & Apparatus, SIC 3841
Sensus Healthcare, Inc. is a medical device company that develops and markets non-invasive superficial radiation therapy systems for treating non-melanoma skin cancer and preventing keloid scars. Operating in a single business segment, the company provides the SRT-100, SRT-100+, and SRT-100 Vision treatment devices, along with clinical consumables. It also delivers maintenance through its Sentinel program, cloud software, and turn-key service agreements that include equipment, technologist staffing, and clinical oversight. Its primary customers include private dermatology practices and radiation oncologists.
The company is headquartered in Boca Raton, Florida. Sensus has installed 955 units across 21 countries, primarily within the United States. It serves clients through a direct domestic sales force and third-party international dealers and distributors in foreign markets, including China.
Summary of the business section of Sensus Healthcare's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sensus Healthcare, Inc.
- Founded
- 2010
- Headquarters
- Boca Raton, FL
- Address
- 851 Broken Sound Parkway Nw, Suite 215 33487
- Phone
- (561) 922-5808
- Website
- sensushealthcare.com
- Employees
- 60, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Berkowitz Pollack Brant, Advisors + CPAs, West Palm Beach, FL
Stock & identifiers
- Ticker
- SRTS
- Exchange
- Nasdaq
- IPO date
- Jun 3, 2016
- Shares outstanding
- 16M, Aug 10, 2026
- Public float
- $70.89M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1494891
- CUSIP
- 81728J109
- ISIN
- US81728J1097
- FIGI
- BBG0074FZRZ0
- Share class FIGI
- BBG0074FZS06
- LEI
- 549300F3JF8NCDJJZW04
- EIN
- 27-1647271
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph C. Sardano | CHIEF EXECUTIVE OFFICER, Director | 1,220,293 |
| Michael Sardano | PRESIDENT AND GENERAL COUNSEL, Director | 159,839 |
| Javier Rampolla | CHIEF FINANCIAL OFFICER | 48,114 |
| Magdalena Martinez | CHIEF OPERATING OFFICER | 12,754 |
| Carlton Chow | Chief Technology Officer | – |
| Eric Sachetta | Director | 296,877 |
| Larry Joseph Biscotti | Director | – |
| Megan Cornish | Director | 32,000 |
| William H. McCall | Director | 355,723 |
| Anthony Benedict Petrelli | Director | 66,466 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $1.26M | $1.26M | $963.84K | $96 | – |
| FY2023 | $687.60K | $687.60K | $404.80K | $32 | – |
| FY2022 | $754.43K | $754.43K | $421.94K | $103 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Joseph C. Sardano Chief Executive Officer | $600.00K | $750.00K | – | $67.86K | $1.42M | +12% |
| Michael Sardano President, General Counsel, Chief Commercial Officer, & Corporate Secretary | $500.00K | $500.00K | $153.20K | $60.72K | $1.21M | -5% |
| Javier Rampolla Chief Financial Officer | $400.00K | $300.00K | – | $52.71K | $752.71K | +15% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 3, 2016
- Offer price
- $5.50
- Securities offered
- 2,000,000
- Gross proceeds
- $11.00M
- Exchange
- Nasdaq
- First trading day
- Jul 26, 2016
- First-day close
- $5.85+6.4%
- Lock-up ends (est.)
- Jan 22, 2017
“Per Unit Total Public offering price $ 5.50 $ 11,000,000 Underwriting discounts and commissions (1) $ 0.385 $ 770,000 Proceeds to Sensus Healthcare, Inc., before expenses $ 5.115 $ 10,230,000 (1) See “Underwriting” on page 103 for a description of additional compensation payable to the underwriters.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“At December 31, 2025, the Company had 60 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 20, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 11, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 3, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 4, 2020 | Delisting | Notice of delisting from exchange (Form 25) |
| Nov 21, 2016 | Delisting | Notice of delisting from exchange (Form 25) |
| Jun 3, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 10, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 30, 2015 | Name change | Name changed from Sensus Healthcare, LLC to Sensus Healthcare, Inc. |
See a number that looks wrong?